<DOC>
	<DOCNO>NCT01212341</DOCNO>
	<brief_summary>Allogeneic natural killer ( NK ) cell ( MG4101 ) manufacture normal healthy donor underwent leukapheresis . These cell process base novel method ex vivo activation expansion use irradiate activated autologous feeder cell system . MG4101 anti-tumor activity various tumor include malignant lymphoma vitro well vivo tumor model .</brief_summary>
	<brief_title>Allogeneic Natural Killer ( NK ) Cell Therapy Patients With Lymphoma Solid Tumor</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<criteria>Age 18 year old Histologically cytologically confirm malignant lymphoma solid tumor After failure standard treatment KPS &gt; 70 ECOG PS 02 Adequate bone marrow , renal , liver function Expected survival least 3 month Informed consent Pregnancy lactate woman HIV patient Prior exposure cellbased therapy Hypersensitivity interleukin2 Patients autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Allogenetic NK cell</keyword>
	<keyword>Lymphomas</keyword>
	<keyword>Solid tumor</keyword>
</DOC>